European regulators recommend expanding once-weekly growth hormone therapy to include children born small for gestational age ...

Johnson & Johnson's prostate cancer drug Erleada used with hormone-blocking therapy six months before and after prostate ...

For patients, this means many may be spared the physical and emotional burden of chemotherapy and its potential long-term side effects. For health systems, it represents a more efficient and ...

And the potential side effects are related to the fact that they are so powerful, she said. While not everyone who takes ...

Skytrofa is now prescribed for growth hormone deficiency (GHD) in both adults and children ages 1 year and older who weigh at least 11.5 kilograms. Common side effects differ by age. Children often ...

Johnson & Johnson's Erleada drug, combined with hormone therapy, significantly reduces the risk of prostate cancer spread and ...

Johnson & Johnson's Erleada drug, combined with hormone therapy, significantly reduces the risk of prostate cancer spread and death in late-stage studies. Read more at straitstimes.com. Read more at ...

As many as 5,000 women a year with hormone-sensitive breast cancer could benefit ...

Millions of breast cancer patients could be spared chemotherapy with a revolutionary new genomic test, a clinical trial has shown. The most common type of cancer in women in the UK, breast cancer is ...

A new DNA test could help screen whether patients require the treatment or not, according to a new international trial.

Scientists developed a DNA or gene test that can differentiate between patients who are likely to benefit from the treatment and those who are not, a clinical trial has shown.

A study of 4,400 breast cancer patients found that more than two-thirds with low Prosigna gene-test scores could be safely treated with hormone therapy alone. | ITV National News ...